drugset / Trial / NCT02274792
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |